Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use ... “Our AI/ML-driven HG-PRECISE ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

Using state-of-the-art technology, researchers have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical findings could lead to ...

Feng Zhang, 2021 Richard Lounsbery Award recipient, will present the 2024 Lounsbery Lecture on "Exploration of Biological ...

In 2014, CRISPR and CRISPR-associated (Cas ... significant investment challenges since the boom years of 2020 and 2021. However, signs of recovery are emerging, according to data shared by ...

If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful ...